Lung Cancer Clinical Trial
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Summary
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
ECOG performance status of 0-2
Age > 18 years old
Ability to understand and the willingness to personally sign the written IRB approved informed consent document
Estimated life expectancy of 12 weeks or longer
Exclusion Criteria:
Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
Age < 18 years old
Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
Diagnosis of interstitial pulmonary fibrosis
Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?